Csl . Stock News

CSL Limited (OTCMKTS:CSLLY) has been given an average recommendation of Hold by the eight brokerages that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report []

Immunoglobulins are used by the body''s immune system to safely identify and target foreign objects like viruses and pathogenic bacteria. Immunoglobulin recognizes a unique substance of the pathogen, termed antigens. When introduced into the body, the immunoglobulin immediately targets antigens

Zacks Investment Research upgraded shares of CSL (OTCMKTS:CSLLY) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. They currently have $128.00 target price on the stock. According to Zacks, CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma []

CSL (OTCMKTS:CSLLY) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Monday, Zacks.com reports. According to Zacks, CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The companys []

CSL Limited (OTCMKTS:CSLLY) saw a significant growth in short interest in October. As of October 29th, there was short interest totalling 16,600 shares, a growth of 23.0% from the October 14th total of 13,500 shares. Based on an average daily trading volume, of 63,300 shares, the short-interest ratio is presently 0.3 days. CSLLY has been []

Zacks Investment Research lowered shares of CSL (OTCMKTS:CSLLY) from a buy rating to a hold rating in a research report released on Monday morning, Zacks.com reports. According to Zacks, “CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. […]

Zacks Investment Research lowered shares of CSL (OTCMKTS:CSLLY) from a buy rating to a hold rating in a research note released on Tuesday, Zacks.com reports. According to Zacks, CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The []

Transparency Market Research (TMR) has published a new report titled, Subcutaneous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global subcutaneous immunoglobulin market was valued at US$ 4.0 Mn in

MELBOURNE, Australia and KING OF PRUSSIA, Pa., Oct. 18, 2021 /PRNewswire/ -- During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its n

BOCA RATON, Fla., Aug. 26, 2021 /PRNewswire/ -- CSL Plasma today announced it will provide influenza (flu) vaccination vouchers to U.S. plasma donors following the completion of two plasma donations

CSL Limited's (CSLLY) CEO Paul Perreault on Q4 2021 Results - Earnings Call Transcript

KING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force

KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ --  CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug.

CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The compan

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that in